Mesenchymal Stem Cells as A New Approach for the Treatment of Multiple Sclerosis: A Literature Review

被引：4
作者：
Rostami, Amirabbas
Abbasi, Yusef [1 ]
Jamalnia, Sheida [2 ]
Asadian, Asma [3 ]
Enani, Hossein [4 ]
Jafarinia, Morteza [5 ,6 ]
机构：
[1] Yerevan State Med Univ Mkhitar Heratsi, Fac Gen Med, Dept Internal Med, Yerevan, Armenia
[2] Arak Univ Med Sci, Fac Med, Dept Anat, Arak, Iran
[3] Islamic Azad Univ, Dept Nursing & Midwifery, Kazeroun Branch, Kazeroun, Iran
[4] Torbat Heydariyeh Univ Med Sci, Dey Educ Hosp 9, Clin Res Dev Unit, Torbat Heydariyeh, Iran
[5] Islamic Azad Univ, Fac Med, Marand Branch, Marand, Iran
[6] Shiraz Univ Med Sci, Shiraz Neurosci Res Ctr, Shiraz, Iran
来源：
GALEN MEDICAL JOURNAL | 2022年 / 11卷
关键词：
Multiple Sclerosis; Mesenchymal Stem Cells; Human Leukocyte Antigen; EPSTEIN-BARR-VIRUS; STROMAL CELLS; SEX-RATIO; RISK; IMMUNOMODULATION; THERAPY; TRANSPLANTATION; MECHANISMS; SMOKING;
D O I：
10.31661/gmj.v11i.2529
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Multiple sclerosis (MS) is a high-prevalence autoimmune and neurodegenerative disease that affects young adults. An ideal treatment for MS should have two characteristics. First, its immunosuppression and immunomodulation effects reduce the abnormal immune response, and second, it improves repair by enhancing intrinsic repair processes or even cell replacement. Most available therapies have the first characteristic. Recent studies have proposed mesenchymal stem cells (MSCs) as a new therapeutic candidate for MS. Different clinical trials and animal models of MS have shown the therapeutic effect of MSCs. In the current study, we reviewed the therapeutic effects of MSCs in the animal model and patients with MS. [GMJ.2022;11:e2529] DOI:10.31661/gmj.v11i.2529
引用
收藏
页数：9
相关论文
共 67 条
  • [1] Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes
    Abdi, Reza
    Fiorina, Paolo
    Adra, Chaker N.
    Atkinson, Mark
    Sayegh, Mohamed H.
    [J]. DIABETES, 2008, 57 (07) : 1759 - 1767
  • [2] Molecular docking studies and biological evaluation of luteolin on cerebral ischemic reperfusion injury
    Al-Obaidi, Zaid Mahdi Jaber
    Hussein, Yasmeen Ali
    AL-Duhaidahawi, Dunya
    Al-Aubaidy, Hayder A.
    [J]. EGYPTIAN JOURNAL OF CHEMISTRY, 2022, 65 (06): : 433 - 440
  • [3] Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function
    Anderson, Per
    Gonzalez-Rey, Elena
    O'Valle, Francisco
    Martin, Francisco
    Javier Oliver, F.
    Delgado, Mario
    [J]. STEM CELLS INTERNATIONAL, 2017, 2017
  • [4] Environmental factors in multiple sclerosis
    Ascherio, Alberto
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 3 - 9
  • [5] Berebichez-Fridman Roberto, 2018, Sultan Qaboos Univ Med J, V18, pe264, DOI 10.18295/squmj.2018.18.03.002
  • [6] Evaluation of Cytokines in Multiple Sclerosis Patients Treated with Mesenchymal Stem Cells
    Bonab, Mandana Mohyeddin
    Mohajeri, Maryam
    Sahraian, Mohammad Ali
    Yazdanifar, Mahboubeh
    Aghsaie, Aida
    Farazmand, Ali
    Nikbin, Behrooz
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2013, 44 (04) : 266 - 272
  • [7] Bonab MM, 2012, CURR STEM CELL RES T, V7, P407
  • [8] ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
    Browne, Paul
    Chandraratna, Dhia
    Angood, Ceri
    Tremlett, Helen
    Baker, Chris
    Taylor, Bruce V.
    Thompson, Alan J.
    [J]. NEUROLOGY, 2014, 83 (11) : 1022 - 1024
  • [9] Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis
    Cohen, Jeffrey A.
    Imrey, Peter B.
    Planchon, Sarah M.
    Bermel, Robert A.
    Fisher, Elizabeth
    Fox, Robert J.
    Bar-Or, Amit
    Sharp, Susan L.
    Skaramagas, Thomai T.
    Jagodnik, Patricia
    Karafa, Matt
    Morrison, Shannon
    Koc, Jane Reese
    Gerson, Stanton L.
    Lazarus, Hillard M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (04) : 501 - 511
  • [10] Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
    Connick, Peter
    Kolappan, Madhan
    Crawley, Charles
    Webber, Daniel J.
    Patani, Rickie
    Michell, Andrew W.
    Du, Ming-Qing
    Luan, Shi-Lu
    Altmann, Daniel R.
    Thompson, Alan J.
    Compston, Alastair
    Scott, Michael A.
    Miller, David H.
    Chandran, Siddharthan
    [J]. LANCET NEUROLOGY, 2012, 11 (02) : 150 - 156
1234567